Susan G. Komen®
Where the end of breast cancer begins.

Since our founding, Susan G. Komen has been leading the fight to create a world without breast cancer. After nearly four decades we remain committed to doing everything we can to save lives from breast cancer – but we know we cannot do it alone. Thank you to the researchers who partner with us to discover new, more effective treatments and the countless people working on the frontlines to help care for those facing the disease today. Thank you to our corporate partners, donors and thousands of individual fundraisers who fuel our mission and make all our work to save lives possible.

“It is fair to say that in every single advance in breast cancer that we have seen over the last 30 years, the role of an organization like Komen has been enormous, in helping it become a reality.”

ANTONIO WOLFF, M.D.
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins

Together, we’ve made great progress:
• We’ve helped reduce breast cancer mortality rates by 40% since 1989.
• We’ve invested more than $1 billion in research, leading to newer more effective treatments and higher quality of care.
• We’ve invested more than $2.3 billion to advocate on behalf of breast cancer patients and to help millions of people across the world understand their disease, access screening and diagnostic exams, remove barriers to care and support them every step of the way.

Yet despite all our progress...
• Breast cancer is still the most common cancer in women worldwide and the second leading cause of cancer death among women in the U.S.
• Every 2 minutes, somewhere in the U.S., a woman is diagnosed with breast cancer.
• More than 42,000 people are expected to die from breast cancer in the U.S. this year alone.

For some the image that comes to mind is that of a sea of pink clad women and men walking in one of our signature events. For others, it’s the profile of a researcher peering into a microscope or the face of the doctor that is telling you your life has changed forever.

The truth is Susan G. Komen is all of those things – and so much more.

Like many of my colleagues, I was drawn to this organization because of my personal experience with breast cancer. Not only am I a breast cancer survivor, but I also lost my mother to metastatic breast cancer and I have two adult daughters. When you have been touched by this disease, you often begin to focus on the things that really matter in this world, like spending time with family and making a difference by helping others. Our history is filled with stories like mine. It’s one of ordinary people coming together to do extraordinary things to help their neighbors and to create a better world for their children.

Through the power of our collective voice, we have led a revolution in the way the world thinks about and treats breast cancer and we have helped save countless lives along the way. Now, after nearly four decades of leadership, it’s time for another Komen-led revolution.

As I write this letter, the world is in the grips of a global pandemic that is changing the way people engage with the health care system and with each other. Now is the time to leverage technology-driven solutions to accelerate research and improve patient care. Now is the time to directly support people facing both the uncertainty of breast cancer and financial hardships caused by the disease and our current economic crisis. Now is the time to achieve health equity, so everyone can enjoy the benefits of our research discoveries and have the same chance of living longer, better lives.

To lead this new revolution, we are undertaking a transformation of our organization to create efficiencies and expand our reach to all people. We are finding new creative ways to come together to support each other and raise needed funds. And we are leading a movement to create transformational relationships - for us, for our partners and for everyone impacted by a breast cancer diagnosis.

THANK YOU FOR BEING OUR PARTNERS IN THIS FIGHT.

PAULA SCHNEIDER, CEO
“Susan G Komen and the work that they’re supporting is so critical to people like me...so that we can improve the care, not only of the people we see every day in our clinics, but in the nation, and in the world. We need to work to continue to make breakthroughs. Too many women still die of breast cancer. We also need to do work to break down the barriers of access to care for many women in our country and beyond. And the cool thing is that Susan G. Komen is in there for all of those areas.”

ANN PARTRIDGE, M.D.
Dana Farber Cancer Institute, Harvard University
The Susan G. Komen Difference

Susan G. Komen is the breast cancer organization of choice for organizations and individuals looking to make a significant impact in the fight against breast cancer. Komen’s unmatched national infrastructure and global, grassroots footprint enables us to provide innovative and impactful solutions quickly at scale.

Our unique combination of breast cancer expertise, compassionate support and advocacy has cemented us as the most respected and invaluable partner in the fight against breast cancer among patients and their families, researchers, health care providers and policy makers.

ACHIEVEMENTS IN 2019

RESEARCH | ACTION | CARE | COMMUNITY

RESEARCH

- We convened the first ever Susan G. Komen Breast Cancer Disparities Summit to hear from leaders in the field on the next steps needed in this critical area.
- Komen launched the Clinical Trials Initiative with the goal of helping people with any stage of breast cancer find and participate in clinical trials.
- We piloted our Big Data for Patients (BD4P) program, with the goal of empowering patient advocates with the tools and resources needed to confidently participate in and inform discussions of big data projects.
- Komen partnered with Cancer Australia to fund a research grant to Dr. Sarah-Jane Dawson from the University of Melbourne. Through this grant, Dr. Dawson will develop a “liquid biopsy” test to detect tumor-specific DNA circulating in the blood stream and validate the test’s ability to identify patients with the highest risk of breast cancer relapse. The test should also provide information on how best to treat these patients.
- Nadine Tung, M.D. announced results of the INFORM trial at the 2019 San Antonio Breast Cancer Symposium (SABCS). This study, funded in part by Komen, showed that both cisplatin chemotherapy as well as standard chemotherapy with doxorubicin and cyclophosphamide are effective treatment options for HER2-negative breast cancer patients with a BRCA1/2 gene mutation.
- Komen Scholar Regina Barzilay, Ph.D., and colleagues developed Artificial Intelligence (AI) to better predict the onset of breast cancer. Using mammogram images, their model can predict if someone is likely to develop breast cancer up to 5 years earlier than traditional mammogram.

ACTION

- Launched the Susan G. Komen Center for Public Policy, a new unifying identity for the critical local and national work we are doing together to take action through public policy in the fight against breast cancer.
- Gathered more than 250 advocates to Washington, D.C. in May for the 2019 Komen Advocacy Summit.
- Introduced the Access to Breast Cancer Diagnosis Act (H.R.2428/S.3216) in the U.S. House and Senate.
- Komen led the introduction and passage of nine pieces of legislation in seven states.
- Held 15 state advocacy training events, providing engagement with advocates across the country and cemented Komen’s position as a leader in breast cancer advocacy.
- Grassroots advocates now active in every state across the country with 11.6k messages sent to lawmakers in 2019.

CARE

- More than 15,000 people contacted Komen’s free Breast Care Helpline seeking support.
- Nearly 3 million people visited Komen’s comprehensive “About Breast Cancer” section of komen.org.
- Over 8,000 individuals going through treatment received financial assistance from Komen to help cover a variety of related expenses.

COMMUNITY

- Komen hosted 52 events for individuals living with metastatic breast cancer (MBC) through the MBC Impact Series. These events included educational conferences, symposia, retreats, webinars and networking events.
- Komen hosted two In My Own Voice (IMOV) events convening 42 African American women living with MBC to learn about the latest advances in MBC treatment and share their unique experiences living with the disease.
- Komen provided nearly 84,000 community-based services, including:
  - Nearly 45,000 breast cancer screening services.
  - More than 18,000 diagnostic services.
  - More than 250 treatments services.
  - Nearly 200 genetic testing services were provided.

• Komen partnered with Cancer Australia to fund a research grant to Dr. Sarah-Jane Dawson from the University of Melbourne. Through this grant, Dr. Dawson will develop a “liquid biopsy” test to detect tumor-specific DNA circulating in the blood stream and validate the test’s ability to identify patients with the highest risk of breast cancer relapse. The test should also provide information on how best to treat these patients.

• Nadine Tung, M.D. announced results of the INFORM trial at the 2019 San Antonio Breast Cancer Symposium (SABCS). This study, funded in part by Komen, showed that both cisplatin chemotherapy as well as standard chemotherapy with doxorubicin and cyclophosphamide are effective treatment options for HER2-negative breast cancer patients with a BRCA1/2 gene mutation.

• Komen Scholar Regina Barzilay, Ph.D., and colleagues developed Artificial Intelligence (AI) to better predict the onset of breast cancer. Using mammogram images, their model can predict if someone is likely to develop breast cancer up to 5 years earlier than traditional mammogram.
REVEREND TAWANA DAVIS has been living with stage IV, metastatic HER2 positive breast cancer since November of 2016. Since her diagnosis, she has endured several surgeries, hospital stays and near-fatal experiences, but remains committed to advocating for and supporting others impacted by breast cancer.

“I was 23 years old when my mother died from complications of multiple myeloma, which is cancer of the bone marrow. I’ve always been surrounded by cancer survivors, which may have been a way for me to reconcile my own mother’s death. I felt like my mom really didn’t get to live with cancer, she was dying from it. And I wanted to shift that narrative, where cancer doesn’t equate to death. In my own community, oftentimes we call it the “big C,” we don’t even want to say the word, because cancer equals death in our minds. So, it meant a lot to me to serve and volunteer and help breast cancer survivors on their journey, which is something that I did for many years.

I had no idea that I would be diagnosed with the very same disease that I’d been advocating and raising awareness for, but in November 2016, I found a swollen lymph node under my left arm and was diagnosed with breast cancer. It had already metastasized, which was a term that I didn’t know at the onset of my diagnosis, which meant that my cancer had already spread beyond my breast. I’ll be in treatment for the rest of my life. Do I get frustrated? Absolutely. Do I cry? Absolutely. Do I wonder how this is going to end? Absolutely. And then I check myself and I realize that I have another day to watch the sunrise. I have another day to take my grandson to school, and just watch his beautiful smile and beautiful spirit when he comes into the car to greet me.

The Susan G. Komen Colorado MORE THAN PINK Walk® last year was the first event that I was able to do. Before that, I couldn’t be around people because of my compromised immune system, and I couldn’t even stand for long periods of time. So that moment meant so much to me, to be around all these people caring about the cause, whether they were diagnosed, a caregiver, a family member, or just someone who knows someone with breast cancer. Just being around all of that healing, powerful energy was amazing.

While we all want to save the world, we just can’t. It’s about picking your causes and doing the best you can. If your best is $5 and that’s your sacrifice, honor that and wear it proudly and know that you have sown a seed toward saving someone’s life. Because the research that Komen supports is the reason why I am standing here today, alive. I want everyone who donates to know that no matter how big or how small the amount, their donation will help identify how we can better fight this huge, disrespectful beast called cancer.”
In September 2019, the Susan G. Komen Center for Public Policy was formally launched at the National Press Club in Washington, D.C., at an event that featured a discussion moderated by Noam Levey of the Los Angeles Times, about barriers to breast cancer research, detection and treatment, and the role policy plays in creating solutions. Panelists included: Congresswoman Debbie Wasserman Schultz; Claudia Campos, the chief programs officer and mental health director at Nueva Vida; Dr. Regina Hampton, medical director of the Breast Center at Doctors Community Hospital; and Michelle Hedman, a nurse living with metastatic breast cancer.

The Center for Public Policy focuses its work on empowering people with knowledge, connecting advocates together and mobilizing everyone to act. It also serves as a platform to give voice to and meet the needs of breast cancer patients, survivors and their loved ones across the country.

The Susan G. Komen Center for Public Policy

Our 2019-2020 Public Policy Priorities:

Advance Breast Cancer Research
- Expand federal funding for all biomedical research, especially breast cancer research conducted at the National Institutes of Health (NIH) and at the Department of Defense (DOD).
- Ensure state funding for breast cancer research programs conducted through state institutions continues.
- Increase education about, utilization of and access to clinical trials for all patient populations.

Ensure Access to Affordable, High-Quality Health Care
- Protect access to affordable, high-quality health care for all patients.
- Support Medicaid expansion and expanded eligibility for Medicaid’s Breast and Cervical Cancer Treatment Program (BCCTP).
- Ensure continued access to Medicaid coverage without burdensome restrictions.

Increase Coverage and Access to Breast Cancer Screening and Diagnostic Services
- Protect federal and state funding for the Centers for Disease Control and Prevention’s (CDC) National Breast and Cervical Cancer Early Detection Program (NBCCEDP).
- Modernize state screening programs to expand eligibility and provide breast cancer screening and diagnostic services for additional populations.
- Reduce or eliminate out-of-pocket costs for diagnostic imaging.

Reduce Insurance Barriers to Treatment
- Protect patient preference, enhance coverage, reduce cost and address barriers to breast cancer treatments, including those that would require oral parity, preclude specialty tiers, prevent step therapy protocols, prevent non-medical switching and limit patients’ out-of-pocket costs.
In addition to increased funding, Komen is working to drive change and protect patients through legislation, including:

- **Access to Breast Cancer Diagnosis Act (H.R. 2428/S. 3216)** - This Komen-led legislation will increase access to diagnostic imaging by eliminating cost sharing for patients with private insurance for medically-necessary diagnostic imaging (diagnostic mammography, MRI, ultrasound, etc.).

- **Breast Cancer Research Stamp Reauthorization Act (H.R. 2689/S. 1438)** - Thanks to the hard work of Komen advocates, Congress renewed the two decades old Breast Cancer Research Stamp, which has raised more than $89 million for critical research through the sale of more than one billion stamps. The stamp was set to expire at the end of 2019. Now this life saving program continues!

- **Cancer Drug Parity Act (H.R. 1730/S. 741)** - This legislation will require insurance to cover oral chemotherapy drugs the same as they do for IV, enabling patients to have more options when it comes to their treatment.

- **Metastatic Breast Cancer Access to Care Act (H.R. 2178/S. 1374)** - This legislation will eliminate potentially harmful wait times for patients living with metastatic breast cancer who often have to wait five months for Social Security Disability Insurance and an additional 24 months for Medicare.

Komen’s advocacy also extends to regulations that impact breast cancer patients. Komen and our collaboration partners review proposed rules and submit comment letters to the appropriate agencies to ensure the patient voice and perspective is heard on topics ranging from drug pricing and surprise medical billing to clinical trial eligibility.

**Federal Policy and Advocacy**

Thanks in part to Komen’s efforts, the fiscal year 2020 federal budget included the funds above.
Policy and Advocacy

This year, Komen doubled down on our public policy and advocacy activities at the state level. By focusing our efforts on a handful of issues, we were able to streamline resources and increase our successes both as an individual organization and within coalitions. Some of our accomplishments include:

- **Arkansas:** Komen led legislation that would prohibit step therapy protocols for metastatic cancer patients.
- **Colorado:** Komen led legislation to require full coverage for diagnostic imaging, as well as legislation to reauthorize the Breast and Cervical Cancer Treatment Program.
- **Louisiana:** Komen led legislation to eliminate out-of-pocket costs for diagnostic imaging, as well as legislation to prohibit step therapy for patients with metastatic cancer.
- **New York:** Komen supported coalition efforts to pass non-medical switching legislation.
- **Ohio:** Komen advocated for an amendment in the budget to expand access to the Ohio Breast and Cervical Cancer Project by increasing eligibility to 300% (FPL).
- **Tennessee:** Komen supported coalition efforts to oppose the creation of state Medicaid block grant funding.
- **Texas:** Komen advocated for an amendment in the budget to expand access to the Ohio Breast and Cervical Cancer Project by increasing eligibility to 300% (FPL).

Grassroots Advocacy

As our state and federal advocacy efforts continue to expand, so does our grassroots presence! We have grassroots advocates in every single state that are active within our new our new engagement platform. The Komen Action Center allows advocates to easily engage on local and national advocacy campaigns and provides the Center for Public Policy with real-time and dynamic reporting to further strategize our grassroots engagement.

Our growth has also allowed us to increase our social media followers and reach on both Facebook and Twitter. Connecting directly with our constituents gives us the opportunity to build relationships with key grassroots advocates throughout the country and provide timely and direct updates on our work.

Research

Since our very beginning, Komen has focused on investing in breakthrough research. In our early days, research focused on basic biology to better understand breast cancer. Over the years, Komen’s research investment has shifted to focus more on developing new, more effective treatments—especially for the most aggressive and deadly breast cancers.

“I have been living with metastatic breast cancer for over 20 years now. I’ve had access to treatments that wouldn’t be available if it wasn’t for early-stage (basic) research funded through Komen.”

SANDI SPIVEY
Komen Scholar and Advocate in Science
Big Data for Breast Cancer - BD4BC

Komen envisions a world in which health care is an integrated web of information, so patients are better informed and feel empowered to participate in their care, data systems are linked and accessible, and electronic health records provide evidence-based support for clinical decision-making. While Big Data applications hold immense promise for research, the capabilities of data science and technology have not revolutionized the health care industry the way they have other industries (e.g. financial industry, transportation). Komen’s Big Data for Breast Cancer (BD4BC) Initiative seeks to accelerate scientific discoveries and improve the patient experience for everyone touched by breast cancer.

THROUGH BD4BC, WE WILL:

• Empower people to make data sharing understandable and easy to do.
• Overcome current challenges of incorporating big data applications into breast cancer research and clinical care.
• Fund research projects leveraging data science to improve breast cancer outcomes and save lives.

Scientist Spotlight

LAUREN MCCULLOUGH, PH.D., OF EMMORY UNIVERSITY is using Big Data to study the different factors which can lead to racial differences in mortality from breast cancer. She is examining disparities that exist among different racial and ethnic groups, combined with socioeconomic status and geographic location, such as whether the person lives in an urban or rural area. This work will help to identify and evolve innovative solutions to address racial disparities in outcomes in metastatic breast cancer.

THE NATIONAL CANCER ADVISORY BOARD (NCAB) WORKING GROUP ON DATA SCIENCE, chaired by Komen Scholar Mia Levy, M.D., Ph.D. and Charles Sawyers, M.D., and which included four other Komen Scholars and grantees, as well as Dr. Kim Sabelko, Komen’s senior director of Scientific Strategy & Programs, submitted its final report to the NCAB in June 2019. The report provides recommendations on opportunities for the National Cancer Institute (NCI) in data science, Big Data, and bioinformatics to further cancer research. Areas covered included:

• Support of data science training and workforce development
• Developing machine learning infrastructure for cancer research
• Facilitating the appropriate use of real-world data
• Enabling the cultural shift toward data sharing

Investing in the next generation of breast cancer researchers

Komen has invested more than $107 million since 2008 to support 243 emerging leaders in the field of breast cancer research. These Career Catalyst Research (CCR) grants equip early-career investigators with resources and connections needed to establish or expand their research program, explore new or high-risk ideas and emerge as key leaders in the fight against breast cancer. Selected through a rigorous peer review process, these Early Career Investigators are exploring innovative ways of looking at breast cancer, often resulting in groundbreaking discoveries.

“Komen supporting young investigators is really building the foundation, not just for new, innovative minds who are bringing different concepts to breast cancer research, but laying the foundation for decades of excellent breast cancer researchers in the future, like me, who might not have otherwise had a chance to become a breast cancer researcher.”

DAN STOVER, M.D., Ohio State University

Recognizing Scientific Distinction

While we help to nurture researchers early in their careers, many go on to become the leading minds in the field. At the San Antonio Breast Cancer Symposium, Komen presents its highest honors – the Brinker Awards for Scientific Distinction in Basic Science and Clinical Research. This year’s awardees were:

• JANE VISVADER, PH.D., AND GEOFFREY LINDEMAN, M.B.B.S., PH.D., recognized for their significant contributions to our understanding of how normal and cancerous cells develop in the breast.
• MATTHEW J. ELLIS, B.SC., M.B., B.CHIR., PH.D., FRCP., honored for seminal contributions in understanding the genomics of breast cancer and translating this knowledge to the clinic to improve the effectiveness of breast cancer treatment.

Collaborating with the Brightest Minds to Advance Research

Susan G. Komen is privileged to work with some of the leading minds in breast cancer research. Our Scientific Advisory Board and Komen Scholars serve as Komen’s brain trust, helping to guide our research programs. In February, we convened 66 of these leaders in breast cancer research and patient advocacy for provocative discussions about bold questions in breast cancer that will inform our research strategy and Komen’s leadership role.

“Komen’s role is not just as a funder of research, but as a convener of researchers.”

GEORGE SLEDGE, JR., M.D.,
Komen Chief Scientific Advisor, Stanford University
**Achieving Health Equity, Overcoming Disparities**

Komen’s African American Health Equity Initiative aims to identify and address the systemic barriers that drive differences in breast cancer outcomes between African American women and their Caucasian counterparts. Leveraging evidence-informed interventions, we are working to address systemic issues that perpetuate existing breast health inequities in African American communities.

We know we cannot do this work alone. Together, with a diverse set of community partners and stakeholders, we will work to close the gap in outcomes by achieving systemic changes, starting in the 11 metropolitan areas where breast cancer inequities are the greatest. Serving as the national backbone to the initiative, Komen will fund and provide technical assistance and resources to local organizations and coalitions to address the unique drivers of breast cancer disparities in their communities.

**KEY MILESTONES OF 2019**

**Educating Local Leaders to Facilitate Change**

On November 13 - 14, 2019, Komen convened its local leaders from 11 metropolitan areas with the highest disparities for a two-day training on developing shared language, racial health equity, the history of race and racism in healthcare, and how to use data to advance racial health equity.

**Community Engagement**

The 25th Annual Essence Festival provided Komen’s AAHEI and Know Your Girls™ (KYG) campaign the opportunity to engage directly with members of the African American community and disseminate breast health and breast cancer risk reduction education information. The team engaged 117 festival attendees for “girl talks” at the KYG booth, distributed 4,750 pieces of educational materials, and collected contact information from approximately 3,400 attendees.

**Understanding the Drivers of Disparities**

A key part of the AAHEI is understanding the unique drivers of disparities in each focus community through in-depth landscape analyses, which will inform interventions in each community to achieve health equity. As part of this process, we are working with John Snow Inc. (JSI), to collect quantitative data to inform which counties to prioritize for qualitative data collection. The JSI team has also conducted 69 focus groups, engaging a total of 604 participants, to gather qualitative data from African American breast cancer survivors, as well as African American women who have not been diagnosed with breast cancer. In addition, they collected data from African American patient navigators and providers.
Thanks to increased access to affordable early detection and improved treatments, breast cancer mortality rates have decreased by 40 percent since 1989. Yet for many, access to early detection is not enough. Our complicated health care system, financial burdens and other obstacles serve as significant barriers to care. That’s why Komen is increasingly focused on providing direct patient support, through services such as our helpline, patient navigation and treatment assistance programs.

**Breast Care Helpline**

Increasingly, people touched by breast cancer seek out Komen for help understanding their diagnosis and seeking financial and emotional support. Over the last year, more than 15,000 people contacted Komen’s free Breast Care Helpline seeking support. In addition, nearly 3 million people visited Komen’s comprehensive “About Breast Cancer” section of its website during the last year.

**Patient Navigation**

In Fiscal Year 2019, we funded 489 grants to community health partners across the country. Many focused on helping navigate patients through a portion of the continuum of care. For example, 113 or 23.1% included patient navigation services to help people access screening. Another 116 or 23.7% included patient navigation helping people get from screening to diagnosis. And 13.3%, or 65 grants, included navigation from diagnosis into treatment. In addition to these grants, six Affiliates directly provided lay navigation services across the continuum of care.

**Treatment Assistance Program**

Today, Komen’s national Treatment Assistance Program provides financial assistance for people at or below 250% of the federal poverty level to pay for expenses associated with going through breast cancer treatment. The program helps pay for expenses such as: oral pain and anti-nausea medication, oral chemotherapy and hormone therapy, child care and elder care, food, palliative care and other home care, transportation to and from treatment, lymphedema care and supplies, and durable medical equipment. This program served nearly 4,500 people undergoing breast cancer treatment last year.

The demand for this assistance regularly outpaces available funds. However, due to record unemployment levels caused by the COVID-19 health and economic crisis, we expect demand for this assistance to surge over the next year.

Komen hosted a first of its kind Breast Cancer Disparities Summit, which brought together more than 50 experts and emerging leaders in the field of breast cancer disparities research to work on the problem of inequity in breast cancer outcomes.

**Topics Included**

- Identifying genetic and molecular differences among populations
- Creating a risk assessment model for specific populations
- Leveraging Big Data to understand disparities
- Strategizing ways to increase minority representation in research
- Evaluating how financial and/or treatment toxicity impacts survival

As part of Komen’s commitment to addressing breast cancer disparities, four new breast cancer disparities research grants were awarded at this summit to prioritize research designed to understand the biologic, behavioral, social and systemic causes of breast cancer disparities.

- **MARY-CLAIRE KING, PH.D.**, of The University of Washington will use new scientific approaches to find the genetic basis for the higher rate of Triple Negative Breast Cancer (TNBC) in African American women. These studies will help inform treatment decisions and improve outcomes in African American women diagnosed with TNBC.

- **HARIKRISHNA NAKSHATRI, PH.D.**, of Indiana University will develop a platform to compare tiny samples of breast tumor, tissue around the tumors, and normal breast tissue from women of African, European and other ancestries. He will study how breast tissue biology differs between these populations and how genetic ancestry can impact breast cancer outcomes.

- **ANNE ROSITCH, PH.D.**, of Johns Hopkins University will address the disparity in breast cancer mortality in low resource settings by implementing and evaluating patient advocacy, navigation and referral programs in Tanzania. This work will help patients overcome barriers to care and improve breast cancer outcomes in low-income areas across the globe.

- **BRYAN SCHNEIDER, M.D.**, of Indiana University will study how genetic ancestry affects how African American women respond to breast cancer therapy, especially treatment induced side effects, and build a shared decision making tool that will help patients work with their physicians to make the best treatment decisions.
MBC Community Voice and Support

Komen’s MBC Impact Series
To help support those living with metastatic breast cancer, Komen with the help of our industry and research partners, launched the MBC Impact Series, a collection of local events that connect people living with MBC and their caregivers with the latest research and medical news. Komen hosted 52 events, including 26 conferences, 16 educational events, 6 retreats, and 4 webinars/online learning series. Many of these events also provided a live-stream to ensure people not able to attend in person could benefit from the information provided.

In My Own Voice
To give African Americans living with MBC a safe place to share their experiences with each other and ensure their voice is heard by researchers, Komen hosted its second In My Own Voice focus group in FY20. We provided attendees information regarding the latest MBC research and clinical trials and created space for participants to share their experiences, challenges, need, coping strategies and resilience approaches to guide Komen’s programming and outreach efforts for this community.

“We can be heard...we can have a voice that people can hear us. This word can be published. It could be seen. It can make a difference. It could change things.”
2019 IN MY OWN VOICE PARTICIPANT

“I think we should have a seat at the table - at every table. Not too many black women are involved in research advocacy, which is very important. Not too many black people are involved in going to see our Congressional leaders [but that is important too] because from Congressional leaders hearing our stories, that’s how bills are getting passed.”
2019 IN MY OWN VOICE PARTICIPANT
Fundraising

The Susan G. Komen 3-Day® is a 60-mile walk for women and men who are seeking a greater sense of community and wanting to make a significant impact in the fight to end breast cancer. Participants raise a minimum of $2,300 and walk an average of 20 miles a day for three consecutive days, educating tens of thousands of people about breast health and raising funds to help support breast cancer advocacy, research, patient support and care. Over the past 17 years and 177 events, the Komen 3-Day has raised more than $863 million. Hosted across seven cities, the 3-Day was a tremendous success.

$15.8 MILLION RAISED

6,280 WALKERS going the full 60 mile distance, across 7 nationwide events

746 WALKERS going the 20 mile distance, across 7 nationwide events

1,050 SURVIVORS

1,760 CREW

Thanks to our Sponsors: Bank of America | Amgen | Mohawk
Fundraising

Over the past year we continued the evolution of the series begun in 2018, transitioning our signature fundraising event – the Race for the Cure® series – into a more engaging MORE THAN PINK Walk®. This year, almost 60 markets across the U.S. hosted the revitalized family-friendly event. Participants of all ages and abilities came together to remember those we’ve lost, celebrate those that have survived, honor those currently living with the disease and unite as a community.

The MORE THAN PINK Walk® event experience is designed to give participants a closer look at how their efforts are making a significant impact in critical breast cancer research, action with public policy advocacy, and patient care in their local community.

Corporate Partners
Fueling Our Work to Save Lives

Together, we are accelerating discoveries and transforming the future of breast cancer care.

While the term “partnership” simply means an agreement between two or more organizations, our partners are more than just transactional business relationships. They share our vision for a world without breast cancer and our passion for helping people facing this deadly disease. And they not only help fuel our work, they stand by our side, making our mission a part of their missions.

**WALGREENS** - Thanks to the generosity of our friends at Walgreens and their customers, we are set to launch a new research initiative that will accelerate discovery into understanding and combatting breast cancer recurrence and metastasis. This is part of Walgreen’s five-year $25 million combined commitment to Komen and the Leukemia & Lymphoma Society.

“At Walgreens, we see the devastating impact of a cancer diagnosis and the challenges people living with cancer and their caregivers face in one of the toughest journeys of their lives. By collaborating with Susan G. Komen, we aim to advance critical needs in research and help families with the everyday challenges of living with breast cancer.”

**RICHARD ASHWORTH**, Walgreens president of operations

**BANK OF AMERICA** - Bank of America serves as the National Presenting Sponsor for both the Susan G. Komen 3-Day®, 60-mile walk series, as well as the national Komen Race for the Cure® and MORE THAN PINK Walk® series of family friendly events across the country. In addition to their sponsorship, Bank of America employees also support Komen across the country by volunteering in their local communities.

Bank of America, which has been a partner since 2009, also helps support Komen through its Pink Ribbon banking affinity products, which have raised more than $10.3 million to date.
Corporate Partners

“My care team told me that if I had been diagnosed eight years earlier, without the research and knowledge that we have today, they would have taken my breast. This research changed my life. Without it, I would have undergone chemotherapy and likely early menopause. Without it, I wouldn’t have been given the chance to have my son. When I think about what Komen is doing through research, I know that it is truly changing the outcome for a lot of people. Bank of America recognizes this and the difference that Komen is making in the fight against breast cancer – lives saved, breasts saved, quality of life changed. You see the tangible differences that have been made and you know that the dollars are making a difference. When I look at all of this, I wonder, “why wouldn’t you support Komen?”

KIM HAMSTEAD,
SVP, Affinity Marketing at Bank of America, Breast Cancer Survivor

HINT – Komen continues to attract exciting new partners who are helping to expand our reach and generate critical funds for our work to help fight breast cancer. For example, Hint and its retailers raised $380,000 for our mission this October through the sale of Pink Variety Packs and other products.

FORD - Ford Motor Company is celebrating 25 Years of Partnership, having dedicated more than $137 million to support our mission and save lives. In the most recent year, Ford’s support has been focused on helping patients overcome transportation challenges to their care through support of our Treatment Assistance Program.

“I feel fortunate to be part of a company that has been committed to the fight for 25 years. At the time of my mother’s diagnosis, I had recently started working for Ford Motor Company, and although I was familiar with Ford Warriors in Pink® and their affiliation with Susan G. Komen®, I wasn’t yet aware of the seriously positive impact they both have on the breast cancer community, but it didn’t take long for me to be surrounded by it.”

JIM PETERS, Brand Content and Alliances Marketing Manager at Ford Motor Company
Thanks to an innovative collaboration with the Inflammatory Breast Cancer (IBC) Research Foundation and the Milburn Foundation®, we continue to raise funds to invest in critical research focused on inflammatory breast cancer—a aggressive subtype of breast cancer that is challenging to diagnose and treat.

Together, we’ve raised more than $850,000 this past year for research aimed at finding new, innovative diagnostic tools and treatment options for IBC. The partnership, which began in 2016, has now raised over $3 million to date for IBC research.

IBC is a particularly aggressive form of breast cancer because it can be missed on a mammogram, doesn’t usually present with a lump, is often misdiagnosed, and spreads quickly. In fact, about 30 percent of those diagnosed with IBC are initially diagnosed with metastatic disease, meaning their cancer has already spread to other parts of the body. Clinical trials for new therapies often either restrict enrollment of IBC patients or combine their outcomes with non-IBC patients, limiting our understanding of this form of breast cancer.

Driven by a lack of progress for patients in this area, a focus group of clinicians, researchers and advocates who are experts in the field of IBC were convened through this partnership to identify the most critical questions in IBC and IBC research. Through this patient directed conversation, several vital challenges were identified, including how inflammatory breast cancer is defined in the clinic and for research, resulting in new recommendations to address the challenge of diagnosis.

“In our twenty years of IBC research and patient advocacy, we have consistently stressed the need for better definition and diagnostic guidelines for IBC. We are very pleased that this year’s impressive matching campaign will support continued collaborative work to resolve these long-standing issues, resulting in more timely diagnosis and hopefully saving lives that would have been stolen by IBC.”

GINNY MASON, Executive Director of the IBC Research Foundation

“By working hard together, this partnership has amplified the strengths of each organization to bring a potentially significant advancement in IBC research to fruition.”

BRYON DAVIS, President and CEO of the Milburn Foundation

Kathy Giller
A GIFT TO HELP MEN WITH BREAST CANCER

“When you are living with metastatic breast cancer, time is all you crave. Time to be with the ones you love, time to create new memories for those who will be left behind and time to be grateful for the time you have. Time is everything when you learn that suddenly time will be short. When my husband Lee was diagnosed with Stage IV, he was told that the average life expectancy with the volume of cancer that he had was about 26 months. He lived almost five years with the disease. We knew there was no cure but were encouraged that many treatment options were available. Lee’s first line of treatment was a clinical trial for a class of drugs called PARP inhibitors. We were fortunate that Lee fit the criteria exactly for the participants they were seeking. There were other trials, but Lee was excluded from some simply because he was male. In the years after Lee’s death, I have searched for ways to bring purpose to my life, while honoring Lee’s. The organization that has always supported us from Lee’s initial diagnosis, through his recurrence and beyond, is Susan G. Komen. I was so grateful that Komen opened its arms to me.”

John and Susan Dorr
PLANNING TO MAKE A DIFFERENCE FOR THE FUTURE

Having been touched by breast cancer, the Dorrs wanted to ensure that they are able to leave a legacy of supporting research. That’s why they chose to support Komen’s work to discover breakthroughs and help people in need now and in the future through their Individual Retirement Account (IRA) as part of their estate plan.

“God has blessed all of us with various levels of material and monetary wealth, no matter how large or small. It is ours to manage and use while we are living this life. We can share our blessings with others and help the future generations, whether family or not.”

Cathy Bernard
BREAST CANCER SURVIVOR

Not only is she a breast cancer survivor, but her mother died from metastatic breast cancer and both of her brothers had prostate cancer, including her older brother who died from the disease. This experience has inspired Cathy to become a passionate advocate and donor for research.

“I don’t want anyone else to go through what I did. I know that research is the key to end this so that is why I support Komen.”
Thank you for saving lives

Special thanks to the members of our 3-Day Lifetime Commitment Circle, which is a special group of dedicated participants of the 3-Day who have raised at least $100,000 individually, or at least $1,000,000 as a team.

2018
Jeanie Antonioni, The Cup Crusaders
Tracie Audifferen, Powered by Optimism®
Amparo Baidemor, Thinking Pink
Michelle Bencik, Pink Soles in Motion
D’Lyn Biggs, Team Tiara
Rachel Brown, Bouncin’ Buckeyes
Kathleen Butler, Team Girlapalooza
Stephanie Capaccio, Tulips for TaTas
Sue Cayer, No More Goodbyes
Jennifer Chapman, Grand Ta Tas
Sue Cloonan, Walking and Wine-ing
Jennifer Chapman, Grand Ta Tas
Sue Cloonan, Walking and Wine-ing
Julie Copaken, The Keepers
Cynthia Crisp, Wild Women Originals
Kimberly Crist, C-Side Sisters
Jagdish Dalal
Kathy DiRusso, The Cup Crusaders
Loretta Englishbee, Team Bee
Karen Feinstein, Boxing Babes
Lynne Felker Hines, Pink Panthers
Cora Fong-Congelliere, Surf City Tittys
Martha Geller, Resistencia
Liz Goldman
Jim Hillmann, Coconutter Strutters
Carol Holt, Wild Women Originals
Mary Ann Isaac, Chicks for a Cure
Penny Kellam, Kindred Spirits
Candice Kiss
Alycia, Klein, Save The Sisters
Roslyn Konter, Angels 4 Angels
Dacia Kyle, Team WISH Arizona
Burt Lipshee, JuJu’s Girls (and Boys)
Julie Lobdell, Team Girlapalooza
Stella Lowe, Team Walking On
Jane Malyn
Debbie McCarron, Surf City Tittys
Patricia Miller
Lucy Millman, Sole Sisters!
Beth Northman, BC Babes
Christine Pak
Debby Rich, Angels for the Cure
Patricia Rieder, Pink Soles in Motion
Karen Rush
Bernadette Schulz, Boxing Babes
Betsy Sears, Ta-Ta’s from KC
Joanne Seneta, The Pink Angels
Carol Sheldon, DHL Dynamos
Janice Shore Hines, Pink Pathers
Bert Stein
Mary Tengra, No Walker Left Behind
Holly Thomson, Team WISH Arizona
Riley Weston, Faith Girlz
Christi-Ann Wiltberger, Grand Ta Tas
Rina Wolfe, Angels 4 Angels
Cathy Youngling, Are We There Yet?
Karen McEnheimer, Traveling TaTa’s
George Nummer, Three Days of Magic
Karen RADtke, VI Sisters Walking
Jennifer Rosado, Lori’s Breast Friends
Ann Seiberlich, Sisters 4 Sisters
Marcy Shiner Eddin
Sharon Slosarik, Friends with Heart + Richard Tapia
Trish Taylor, Mor Furniture

2019
Sheryl Cowan, STEPS
Joanne Bidwell, RAD GALS AND PALS
Dana Bilbray, STEPS
Lindsey Bock, Ta-Ta’s from KC
Leslie Chu, Wild Women Walking for A Cure
Sheryl Cowan, STEPS
Karen Eickemeyer, No mercy for breast cancer
Jerri Johnson, Boobies Make Me Smile
Amy Kowalchyk, Save the Boobies Dallas
Pala Liske, Wild Women Walking for a Cure
Heidi Probst, Mor Furniture
Mary Anne Williams, Breast Defense League

2020
Ellen Banta, The VooDoo Dolls
Joanne Bidwell, RAD GALS AND PALS
Dana Bilbray, STEPS
Lindsey Bock, Ta-Ta’s from KC
Leslie Chu, Wild Women Walking for A Cure
Sheryl Cowan, STEPS
Karen Eickemeyer, No mercy for breast cancer
Jerri Johnson, Boobies Make Me Smile
Amy Kowalchyk, Save the Boobies Dallas
Pala Liske, Walking with Purpose
Amy Nadeau
Sallie Reeves, Wild Women Walking for a Cure
Peggy Paul, Wild Women Walking for a Cure
Carol Ann Payne-Johnson
Heidi Probst, Boobie Brigade
Jake Stefan
Mary Anne Williams, Breast Defense League
Komen Leadership

Board of Directors
Peter D. Brundage, Chair of the Board of Directors
Kaye Ceille, Senior Vice President, Avis Budget Group
Ed Dandridge, Global Chief Marketing and Communications Officer, AIG General Insurance
Susannah Gray, Executive Vice President, Finance and Strategy for Royalty Pharma
Jerri Johnson, Executive Director, Business Technology Walt Disney Company. Living with metastatic breast cancer
Kwanza Jones, CEO Kwanza Jones & José E. Feliciano SUPERCHARGED Initiative
Eugene Kim, CEO of The Walking Company
Doug Knutson, MD, System Vice President for Quality and Patient Safety at OhioHealth
Christina Minnis, global head of Acquisition Finance and co-head of the Americas Credit Finance Group at Goldman Sachs
Kristin Nimsger, CEO of Social Solutions, Inc.
John R. O’Neil, senior partner at the global law firm of Kirkland & Ellis
Stephanie Stahl, board member of Dollar Tree, Inc., Knoll, Inc., CHOPT Creative Salad Co.

Komen Executive Leadership Team
Paula Schneider, President and CEO
Dana Brown, SVP, Chief Strategy & Operations Officer
Lori Maris, SVP Affiliate Network
Eunice Nakamura, General Counsel and Corporate Secretary
Catherine Olivieri, SVP Human Resources
Ria Williams, Chief Financial Officer
Victoria Wolodzko, SVP, Mission

Komen Scientific Advisory Board
George Sledge, Jr., M.D., Chief Scientific Advisor
Jennifer Pietenpol, Ph.D., Chief Scientific Advisor
Carlos L. Arteaga, M.D.
Alan Ashworth, Ph.D., FRS
Myles Brown, M.D.
Lisa Carey, M.D.
Sandy Finestone, Psy.D., Komen Advocate in Science
Lisa Newman, M.D., M.P.H.

Komen Scientists
Benjamin Anderson, M.D.
Regina Barzilay, Ph.D.
Abenaa Brewster, M.D., M.H.S.
Joan Brugge, Ph.D.
Mary (Nora) Disis, M.D.
Susan Domchek, M.D.
Matthew Ellis, M.B. B.Chir, Ph.D.
Sharon Giordano, M.D., M.P.H.
Joe Gray, Ph.D.
Dawn Hershman, M.D., M.S.
Reshma Jagsi, M.D., D.Phil.
Cheryl Jernigan, C.P.A., FACHE Komen Advocate in Science
Marian Johnson-Thompson, Ph.D. Komen Advocate in Science
Yibin Kang, Ph.D.
Keith Knutson, Ph.D.
Ian Krop, M.D., Ph.D.
Adrian Lee, Ph.D.
Mia Levy, M.D., Ph.D.
Jennifer Ligibel, M.D.
David Livingston, M.D.
David Mankoff, M.D., Ph.D.
Ingrid Mayer, M.D., M.S.C.I.
Donald McDonnell, Ph.D.
Anne Meyn, M. Ed. Komen Advocate in Science
Kathy Miller, M.D.
Gordon Mills, M.D., Ph.D.
Elizabeth Mittendorf, M.D., Ph.D.
Elizabeth Morris, M.D.
Harikrishna Nakshatri, B.V.Sc., Ph.D.
Steffi Oesterreich, Ph.D.
Olufunmilayo Olopade, M.D.
Julie Palmer, Sc,D., M.P.H.
Ben Ho Park, M.D., Ph.D.
Ann Partridge, M.D., M.P.H.
Edith Perez, M.D.
Charles Perou, Ph.D.
Kornelia Polyak, M.D., Ph.D.
Lajos Pusztai, M.D., D.Phil.
Amelie Ramirez, Dr.P.H., M.P.H.
Jeffrey Rosen, Ph.D.
Bryan Schneider, M.D.
Rebecca Seago-Coyle, M.A.
Barbara Segarra-Vazquez, M.T., DHSc. Komen Advocate in Science
Sohrab Shah, Ph.D.
Sandra Spivey, M.B.A., Komen Advocate in Science
Melinda Telli, M.D.
Geoffrey Wahl, Ph.D.
Meryl Weinreb, Komen Advocate in Science
Alana Welm, Ph.D.
Julia White, M.D.
Antonio Wolff, M.D.
## Consolidated Statement of Financial Position

**Fiscal Year Ended March 31,**

<table>
<thead>
<tr>
<th></th>
<th>2019</th>
<th>2020</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ASSETS:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cash and cash equivalents</td>
<td>68,889,183</td>
<td>62,456,354</td>
</tr>
<tr>
<td>Investments</td>
<td>154,678,179</td>
<td>115,861,335</td>
</tr>
<tr>
<td>Receivables</td>
<td>31,962,593</td>
<td>25,625,563</td>
</tr>
<tr>
<td>Prepaid expense and other assets</td>
<td>2,467,629</td>
<td>2,632,854</td>
</tr>
<tr>
<td>Property and equipment, net</td>
<td>1,182,326</td>
<td>993,409</td>
</tr>
<tr>
<td><strong>Total Assets</strong></td>
<td><strong>259,179,910</strong></td>
<td><strong>207,569,515</strong></td>
</tr>
<tr>
<td><strong>LIABILITIES:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Accounts payable, accrued expenses, and other payables</td>
<td>8,739,177</td>
<td>8,037,032</td>
</tr>
<tr>
<td>Deferred revenue and rent</td>
<td>1,233,217</td>
<td>937,268</td>
</tr>
<tr>
<td>Grants payable, net</td>
<td>84,801,351</td>
<td>45,791,924</td>
</tr>
<tr>
<td><strong>Total Liabilities</strong></td>
<td><strong>94,773,745</strong></td>
<td><strong>54,766,224</strong></td>
</tr>
<tr>
<td><strong>NET ASSETS:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>With Donor Restrictions</td>
<td>98,533,872</td>
<td>66,036,129</td>
</tr>
<tr>
<td>Without Donor Restrictions</td>
<td>65,872,293</td>
<td>86,767,162</td>
</tr>
<tr>
<td><strong>Total Net Assets</strong></td>
<td><strong>164,406,165</strong></td>
<td><strong>152,803,291</strong></td>
</tr>
<tr>
<td><strong>Total Liabilities and Net Assets</strong></td>
<td><strong>259,179,910</strong></td>
<td><strong>207,569,515</strong></td>
</tr>
</tbody>
</table>

## Consolidated Statement of Activities

**Fiscal Year Ended March 31,**

<table>
<thead>
<tr>
<th></th>
<th>2019</th>
<th>2020</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PUBLIC SUPPORT AND REVENUE:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contributions</td>
<td>115,145,655</td>
<td>137,542,578</td>
</tr>
<tr>
<td>Komen Race for the Cure &amp; Breast Cancer 3 Day</td>
<td>84,572,385</td>
<td>72,646,850</td>
</tr>
<tr>
<td>Less: Direct benefit to donors and sponsors</td>
<td>(14,953,516)</td>
<td>(14,295,715)</td>
</tr>
<tr>
<td><strong>Net Public Support</strong></td>
<td><strong>184,764,524</strong></td>
<td><strong>195,893,713</strong></td>
</tr>
<tr>
<td><strong>REVENUE:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Investment Income/(Loss)</td>
<td>8,074,733</td>
<td>(13,483,253)</td>
</tr>
<tr>
<td>Other Income</td>
<td>1,046,422</td>
<td>648,191</td>
</tr>
<tr>
<td><strong>Total Net Public Support and Revenue</strong></td>
<td><strong>193,885,679</strong></td>
<td><strong>183,058,651</strong></td>
</tr>
<tr>
<td><strong>EXPENSES:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Program Services</td>
<td>144,209,959</td>
<td>121,084,304</td>
</tr>
<tr>
<td>Management and General</td>
<td>25,857,357</td>
<td>30,978,821</td>
</tr>
<tr>
<td>Fundraising</td>
<td>33,312,360</td>
<td>42,598,400</td>
</tr>
<tr>
<td><strong>Total Expenses</strong></td>
<td><strong>203,379,676</strong></td>
<td><strong>194,661,525</strong></td>
</tr>
<tr>
<td>Change in net assets</td>
<td>(9,493,997)</td>
<td>(11,602,874)</td>
</tr>
<tr>
<td>Net Assets, beginning of year</td>
<td>173,900,162</td>
<td>164,406,165</td>
</tr>
<tr>
<td><strong>Net assets end of year</strong></td>
<td><strong>164,406,165</strong></td>
<td><strong>152,803,291</strong></td>
</tr>
</tbody>
</table>
“Komen made me feel like I was not alone fighting cancer.”

*For the purposes of our IRS filing, education includes advocacy and a variety of important patient support services, such as our national Helpline, clinical trial helpline, patient navigation programs, digital and print educational resources, and national and community educational events focused on issues such as disparities and metastatic breast cancer.